Psoriasis is one of the most frequent chronic inflammatory dermatoses in the world, with variable prevalence globally. Important factors in the variation of the prevalence of psoriasis include age, gender, geography, and ethnicity, probably due to genetic and environmental factors. Higher prevalence rates have been...
Find MoreZogenix pays USD 250M upfront Modis clinical drug Zogenix, a pharmaceutical company focused on advancing rare disease therapies, has collaborated with the Modis therapeutics. Modis Therapeutics is a company aiming to advance in mitochondrial biology to develop disease-modifying therapies for rare genetic diseas...
Find MorePsoriasis is a debilitating inflammation of skin affecting approximately 7.4 million adults in the United States. Recent researches demonstrating a surge in the Psoriasis prevalence indicating moderate-to-severe psoriasis, absence of safe, effective and easy to administer therapies has clearly resulted in several m...
Find MorePsoriasis is a skin inflammation which is a papulosquamous disease with variable morphology, distribution, severity, course, and duration.According to the WHO report 2016, studies on Psoriasis epidemiology have demonstrated varying prevalence rates across the globe (0.09–11.4%), with an apparent upward trend in sev...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.